The Five Business Strategies of Vision 110 Stage 1
First written in FY2023. 3 of 8 entries say "Reframed", first in FY2024-Q1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026ReframedAnnual report
「By strongly pursuing the following business strategies, we aim to achieve our performance targets and improve the support and evaluation we receive from stakeholders. Business strategies: (1) expand the development pipeline through proactive in-licensing investment, (2) strengthen the ability to create high-value new drugs that meet medical needs, (3) maximise the uptake of new drugs, (4) promote health-related businesses that generate synergies with the new prescription pharmaceutical business and (5) build a sustainable corporate foundation.」
While carrying forward the 5 business strategies from Stage1, Stage2 organises the means of expanding the development pipeline by placing “proactive in-licensing investment” first. - 2026-04-24Cited as achievedM&A and Subsidiary Changes
「Regarding the new pharmaceutical business, we have pursued business strategies including strengthening our ability to create high-value new drugs that address medical needs, expanding the development pipeline through in-licensing, and maximizing the proportion of new drugs, with the aim of achieving our performance targets and improving support and recognition from stakeholders.」
The business strategies concerning new drug creation, in-licensing, the pipeline and the proportion of new drugs under Vision 110 Stage1 were cited as the performance basis for the transfer decision. - FY2025-H1ReframedAnnual report
「In the fiscal year ending March 2025, the second year of the plan, the company adopted “Achieving transformation” as its management policy and is actively pursuing ① achieving transformation in drug discovery, ② expanding its pipeline, ③ maximizing the uptake of new drugs, and ④ improving cost competitiveness, among other initiatives.」
In its second-year activities, the Company organised the Stage1 business strategies into 4 areas, placing “achieving transformation in drug discovery” first. - FY2024RestatedAnnual report
「As business activities, we actively pursued (1) reform of the drug discovery structure, (2) expansion of the pipeline, (3) maximisation of the uptake of new drugs and (4) improvement of cost competitiveness.」
The Company translated the 5 business strategies under Vision 110 Stage1 into 4 business activities in the first year and continues to pursue them. - FY2024-Q3RestatedAnnual report
「In the fiscal year ending March 2024, the first year of the plan, the company adopted “Growth through renewal of the business structure and new initiatives” as its management policy and is actively pursuing ① renewal of its drug discovery organization, ② expansion of its pipeline, ③ maximizing the uptake of new drugs, and ④ improving cost competitiveness as business activities.」
In its first-year activities, the Company translated the Stage1 business strategies into 4 specific areas: drug discovery structure, pipeline, new drug uptake and cost competitiveness. - FY2024-Q2RestatedAnnual report
「In the fiscal year ending March 2024, the first year of the plan, the company adopted “Growth through renewal of the business structure and new initiatives” as its management policy and is actively pursuing ① renewal of its drug discovery organization, ② expansion of its pipeline, ③ maximizing the uptake of new drugs, and ④ improving cost competitiveness as key business activities.」
In its first-year activities, the Company translated the 5 Stage1 business strategies into 4 specific areas: drug discovery structure, pipeline, new drug uptake and cost competitiveness. - FY2024-Q1ReframedAnnual report
「As key business activities, we are actively pursuing (1) reform of the drug discovery structure, (2) expansion of the pipeline, (3) maximisation of the uptake of new drugs and (4) improvement of cost competitiveness.」
In its first-year business activities for the fiscal year ending March 2024, the Company translated the 5 business strategies under Vision 110 Stage1 into 4 specific areas: drug discovery structure, pipeline, new drug uptake and cost competitiveness. - FY2023First statedAnnual report
「(a) Strengthen the ability to create high-value new drugs that address medical needs; (b) expand the development pipeline through in-licensing; (c) maximize the proportion of new drugs; (d) promote health-related businesses that generate synergies with the new drug business; and (e) build a sustainable corporate foundation.」
The new medium-term plan organizes its initiatives into 5 pillars: new drug discovery capabilities, in-licensed pipeline expansion, new drug mix, health-related businesses and a sustainable corporate foundation.